US FDA approves Takeda, Protagonist's drug for rare blood cancer

Reports

3

Domains carrying it

3

First reported

31 August 2026

Latest report

1 September 2026

◆ Sectors

◆ Where

United States

◆ Timeline

1. 31 August 2026US FDA approves Takeda, Protagonist's drug for rare blood cancerpharma.economictimes.indiatimes.com
2. 1 September 2026Recon: FDA approves Protagonist and Takeda's drug for rare blood cancerraps.org

◆ Connected developments

Situations Wire finds semantically close to this one. Proximity, not cause.

• FDA Approves First Drug of Its Kind for Polycythemia Vera, a Rare Blood Disorder14 reports · 12 domains · 1 September 2026
• Protagonist Therapeutics (PTGX) As MIMRYLO Approval Reshapes The Valuation Debate3 reports · 1 domains · 30 August 2026
• US FDA expands approval for J&J's drug for rare blood disorder2 reports · 2 domains · 25 August 2026
• Pancreatic cancer drug approved by FDA is "exceptional moment," Boston researcher says3 reports · 3 domains · 3 September 2026
• U.S. FDA Grants Accelerated Approval to Bristol Myers Squibb's First CELMoD Therapy ...12 reports · 12 domains · 17 August 2026
• FDA Approves Ropeginterferon Alfa-2b for Essential Thrombocythemia11 reports · 10 domains · 2 September 2026

◆ Share

◆ Evidence

3 reports · 3 domains

• Recon: FDA approves Protagonist and Takeda's drug for rare blood cancerraps.org · 1 September 2026
• FDA OKs Takeda, Protagonist drug for rare blood cancerbiopharmadive.com · 31 August 2026
• US FDA approves Takeda, Protagonist's drug for rare blood cancerpharma.economictimes.indiatimes.com · 31 August 2026